These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

263 related articles for article (PubMed ID: 17449900)

  • 41. Schizophrenia, antipsychotics and metabolic disease.
    Reynolds GP
    J Psychopharmacol; 2007 Jun; 21(4):355-6. PubMed ID: 17656424
    [No Abstract]   [Full Text] [Related]  

  • 42. Olanzapine and weight gain.
    Isaac MB; Isaac MT
    Am J Psychiatry; 2005 Sep; 162(9):1764-5; author reply 1765. PubMed ID: 16135655
    [No Abstract]   [Full Text] [Related]  

  • 43. [Challenges in nutrition-based treatment for weight control in adolescents suffering from schizophrenia].
    Shani M; Levi M; Zalsman G
    Harefuah; 2008 Nov; 147(11):901-5, 939. PubMed ID: 19264012
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Antipsychotic drugs: the weight problem.
    Harv Ment Health Lett; 2000 Dec; 17(6):6-8. PubMed ID: 11114878
    [No Abstract]   [Full Text] [Related]  

  • 45. HTR2C haplotypes and antipsychotics-induced weight gain: X-linked multimarker analysis.
    De Luca V; Müller DJ; Hwang R; Lieberman JA; Volavka J; Meltzer HY; Kennedy JL
    Hum Psychopharmacol; 2007 Oct; 22(7):463-7. PubMed ID: 17702092
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Mechanisms of weight gain induced by antipsychotic drugs.
    Baptista T
    J Clin Psychiatry; 2002 Mar; 63(3):245-6. PubMed ID: 11926725
    [No Abstract]   [Full Text] [Related]  

  • 47. [Weight gain due to anti-psychotic medication].
    Gothelf D; Brand-Gothelf A; Apter A; Phillip M; Weizman A; Fainaru M
    Harefuah; 2000 Apr; 138(7):572-8. PubMed ID: 10883188
    [No Abstract]   [Full Text] [Related]  

  • 48. [Adverse effects of second generation antipsychotic agents].
    Wahlbeck K
    Duodecim; 2003; 119(19):1807-9. PubMed ID: 14601381
    [No Abstract]   [Full Text] [Related]  

  • 49. Memantine-associated reversal of clozapine-induced weight gain.
    Schaefer M; Leopold K; Hinzpeter A; Heinz A; Krebs M
    Pharmacopsychiatry; 2007 Jul; 40(4):149-51. PubMed ID: 17694477
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Introduction: weighing the evidence: weight management insights for treating major mental illness.
    Citrome L
    J Clin Psychiatry; 2007; 68 Suppl 12():4. PubMed ID: 17956149
    [No Abstract]   [Full Text] [Related]  

  • 51. Ethical concerns regarding olanzapine versus placebo in patients prodromally symptomatic for psychosis.
    Block JJ
    Am J Psychiatry; 2006 Oct; 163(10):1838; author reply 1838. PubMed ID: 17012701
    [No Abstract]   [Full Text] [Related]  

  • 52. Weight gain in bipolar disorder: pharmacological treatment as a contributing factor.
    Torrent C; Amann B; Sánchez-Moreno J; Colom F; Reinares M; Comes M; Rosa AR; Scott J; Vieta E
    Acta Psychiatr Scand; 2008 Jul; 118(1):4-18. PubMed ID: 18498432
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Pilot study of the efficacy of an educational programme to reduce weight, on overweight and obese patients with chronic stable schizophrenia.
    Iglesias-García C; Toimil-Iglesias A; Alonso-Villa MJ
    J Psychiatr Ment Health Nurs; 2010 Nov; 17(9):849-51. PubMed ID: 21077409
    [No Abstract]   [Full Text] [Related]  

  • 54. Management of weight gain associated with antipsychotics.
    Birt J
    Ann Clin Psychiatry; 2003 Mar; 15(1):49-58. PubMed ID: 12839432
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Schizophrenia, weight gain and atypical antipsychotics.
    Brown S
    Br J Psychiatry; 2006 Feb; 188():191-2. PubMed ID: 16449712
    [No Abstract]   [Full Text] [Related]  

  • 56. Weight Gain Risk Factor assessment checklist: overview and recommendation for use.
    Treuer T; Pendlebury J; Lockman H; Bushe C; Karagianis J; Raskin J; Lipkovich I
    Neuro Endocrinol Lett; 2011; 32(2):199-205. PubMed ID: 21552187
    [TBL] [Abstract][Full Text] [Related]  

  • 57. DRD4 48 bp VNTR but not 5-HT 2C Cys23Ser receptor polymorphism is related to antipsychotic-induced weight gain.
    Popp J; Leucht S; Heres S; Steimer W
    Pharmacogenomics J; 2009 Feb; 9(1):71-7. PubMed ID: 18332898
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Psychiatric medication induced obesity: an aetiologic review.
    Virk S; Schwartz TL; Jindal S; Nihalani N; Jones N
    Obes Rev; 2004 Aug; 5(3):167-70. PubMed ID: 15245385
    [TBL] [Abstract][Full Text] [Related]  

  • 59. [Overweight and obesity in schizophrenia--much more than a life-style issue!].
    Pollmächer T
    Fortschr Neurol Psychiatr; 2008 Dec; 76(12):697. PubMed ID: 19053011
    [No Abstract]   [Full Text] [Related]  

  • 60. Schizophrenia, antipsychotics, and the metabolic syndrome: is there a silver lining?
    Remington G
    Am J Psychiatry; 2006 Jul; 163(7):1132-4. PubMed ID: 16816213
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.